Proteome analysis - Basis for individualized pancreatic carcinoma therapy?;Proteomanalyse - Basis für individualisierte pankreaskarzinomtherapie?

Internist

Volumn 47, Issue SUPPL. 1, 2006, Pages

  Lohr J M ^a,b   Faissner, R ^a   Findeisen, P ^a   Neumaier, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b II Medizinische Klinik   (Germany)

Author keywords

Chemoresistance; Mass Spectrometry; Pancreatic cancer; Protein profiling; Proteomics

Indexed keywords

PROTEOME;

CANCER SURVIVAL; DISEASE EXACERBATION; DISEASE MARKER; GENOMICS; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TRANSCRIPTOMICS;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PEPTIDE MAPPING; PROTEOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33745129722     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-006-1634-7     Document Type: Review

References (24)

1. Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422: 198-207
2. Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1: 845-867
3. Bhattacharyya S, Siegel ER, Petersen GM, Chari ST, Suva LJ, Haun RS (2004) Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 6: 674-686
4. Brandt R, Grützmann R, Bauer A et al. (2004) DNA microarray analysis of pancreatic malignancies. Pancreatology 4: 587-597
5. Carpelan-Holmström M, Nordling S, Pukkala E et al. (2005) Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 54: 385-387
6. Check E (2004) Proteomics and cancer: running before we can walk? Nature 429: 496-497
7. Chen R, Yi EC, Donohoe S et al. (2005) Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 129: 1187-1197
8. Grønborg M, Bunkenborg J, Kristiansen TZ et al. (2004) Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res 3: 1042-1055
9. Hanash SM, Bobek MP, Rickman DS et al. (2002) Integrating cancer genomics and proteomics in the post-genome era. Proteomics 2: 69-75
10. Hu L, Evers S, Lu ZH, Shen Y, Chen J (2004) Two-dimensional protein database of human pancreas. Electrophoresis 25: 512-518
11. Löhr M (2006) Is it possible to survive pancreatic cancer? Nat Clin Pract Gastroenterol Hepatol 3: 236-237
12. Lu Z, Hu L, Evers S, Chen J, Shen Y (2004) Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics 4: 3975-3988
13. Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S (2004) Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28: 38-44
14. Möller A, Malerczyk C, Völker U, Stöppler H, Maser E (2002) Monitoring daunorubicin-induced alterations in protein expression in pancreas carcinoma cells by two-dimensional gel electrophoresis. Proteomics 2: 697-705
15. Petricoin EF, Ardekani AM, Hitt BA et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577
16. Poland J, Urbani A, Lage H, Schnölzer M, Sinha P (2004) Study of the development of thermoresistance in human pancreatic carcinoma cell lines using proteome analysis. Electrophoresis 25: 173-183
17. Posadas EM, Simpkins F, Liotta LA, MacDonald C, Kohn EC (2005) Proteomic analysis for the early detection and rational treatment of cancer - realistic hope? Ann Oncol 16: 16-22
18. Rosty C, Christa L, Kuzdzal S et al. (2002) Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 62: 1868-1875
19. Shekouh AR, Thompson CC, Prime W et al. (2003) Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 3: 1988-2001
20. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D (2004) Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 64: 9018-9026
21. Sinha P, Hütter G, Kottgen E, Dietel M, Schadendorf D, Lage H (1999) Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and micro-sequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis 20: 2952-2960
22. Sitek B, Lüttges J, Marcus K et al. (2005) Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. Proteomics 5: 2665-2679
23. Villanueva J, Shaffer DR, Philip J et al. (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284
24. Wandschneider S, Fehring V, Jacobs-Emeis S, Thiesen HJ, Löhr M (2001) Autoimmune pancreatic disease: preparation of pancreatic juice for proteome analysis. Electrophoresis 22: 4383-4390